Page last updated: 2024-08-07 15:31:54
Prothrombin
A prothrombin that is encoded in the genome of human. [PRO:DNx, UniProtKB:P00734]
Synonyms
EC 3.4.21.5;
Coagulation factor II
Research
Bioassay Publications (139)
Timeframe | Studies on this Protein(%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 33 (23.74) | 18.2507 |
2000's | 60 (43.17) | 29.6817 |
2010's | 40 (28.78) | 24.3611 |
2020's | 6 (4.32) | 2.80 |
Compounds (75)
Drugs with Inhibition Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
5-(n,n-hexamethylene)amiloride | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
benzamidine | Homo sapiens (human) | Ki | 64.9600 | 4 | 4 |
bis(5-amidino-2-benzimidazolyl)methane | Homo sapiens (human) | IC50 | 31.0000 | 1 | 1 |
bis(5-amidino-2-benzimidazolyl)methane | Homo sapiens (human) | Ki | 238.7599 | 1 | 12 |
camostat | Homo sapiens (human) | IC50 | 0.3990 | 2 | 2 |
camostat | Homo sapiens (human) | Ki | 3.4394 | 1 | 6 |
fidexaban | Homo sapiens (human) | Ki | 2.0000 | 2 | 2 |
n(alpha)-(2-naphthylsulfonylglycyl)-4-amidinophenylalanine piperidide | Homo sapiens (human) | IC50 | 0.6900 | 1 | 1 |
nafamostat | Homo sapiens (human) | IC50 | 1.9000 | 1 | 1 |
sulfaguanidine | Homo sapiens (human) | Ki | 0.0950 | 1 | 1 |
proflavine | Homo sapiens (human) | IC50 | 12.0000 | 1 | 1 |
catechin | Homo sapiens (human) | IC50 | 125.0000 | 1 | 1 |
isoquinoline-1,3,4-trione | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
diphenylcarbazone | Homo sapiens (human) | Ki | 1.7000 | 1 | 1 |
dibrompropamidine | Homo sapiens (human) | Ki | 0.9460 | 1 | 1 |
amiloride | Homo sapiens (human) | IC50 | 135.0000 | 2 | 2 |
captopril | Homo sapiens (human) | Ki | 0.0480 | 1 | 1 |
1,2-di(5-amidino-2-benzofuranyl)ethane | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
hexamidine | Homo sapiens (human) | Ki | 0.2240 | 1 | 1 |
inogatran | Homo sapiens (human) | IC50 | 7.9057 | 3 | 3 |
inogatran | Homo sapiens (human) | Ki | 0.0114 | 3 | 3 |
epicatechin | Homo sapiens (human) | IC50 | 150.0000 | 1 | 1 |
p-Aminobenzamidine dihydrochloride | Homo sapiens (human) | Ki | 95.0000 | 1 | 1 |
mci 9038 | Homo sapiens (human) | IC50 | 0.2200 | 12 | 12 |
mci 9038 | Homo sapiens (human) | Ki | 0.0184 | 9 | 9 |
sivelestat | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
dx 9065 | Homo sapiens (human) | IC50 | 1,366.6667 | 3 | 3 |
dx 9065 | Homo sapiens (human) | Ki | 1,334.5000 | 6 | 6 |
efegatran | Homo sapiens (human) | IC50 | 0.0351 | 8 | 8 |
efegatran | Homo sapiens (human) | Ki | 0.0128 | 6 | 6 |
acetylphenylalanyl-prolyl-boroarginine | Homo sapiens (human) | Ki | 0.0000 | 3 | 3 |
cyanidin | Homo sapiens (human) | IC50 | 0.2500 | 1 | 1 |
foy 251 | Homo sapiens (human) | IC50 | 107.5000 | 1 | 1 |
homonojirimycin | Homo sapiens (human) | IC50 | 34.0000 | 1 | 1 |
l 694,458 | Homo sapiens (human) | IC50 | 78.7600 | 1 | 1 |
melagatran | Homo sapiens (human) | IC50 | 0.5239 | 8 | 10 |
melagatran | Homo sapiens (human) | Ki | 0.0016 | 4 | 4 |
pefabloc | Homo sapiens (human) | IC50 | 62.0000 | 1 | 1 |
razaxaban | Homo sapiens (human) | Ki | 4.8322 | 9 | 18 |
dabigatran | Homo sapiens (human) | IC50 | 0.0046 | 12 | 12 |
dabigatran | Homo sapiens (human) | Ki | 0.0050 | 7 | 7 |
sitosterol, (3beta)-isomer | Homo sapiens (human) | IC50 | 754.9250 | 4 | 4 |
sitosterol, (3beta)-isomer | Homo sapiens (human) | Ki | 0.2672 | 1 | 1 |
bortezomib | Homo sapiens (human) | Ki | 13.0000 | 1 | 1 |
benzamidine | Homo sapiens (human) | IC50 | 440.0000 | 1 | 1 |
benzamidine | Homo sapiens (human) | Ki | 155.1385 | 3 | 13 |
phenylalanyl-prolyl-arginine | Homo sapiens (human) | IC50 | 0.0000 | 1 | 1 |
tosylarginine methyl ester | Homo sapiens (human) | IC50 | 89.0000 | 1 | 1 |
telaprevir | Homo sapiens (human) | IC50 | 1.0000 | 1 | 1 |
bradykinin (1-5) | Homo sapiens (human) | IC50 | 601.0000 | 1 | 1 |
silybin | Homo sapiens (human) | IC50 | 22.9500 | 2 | 2 |
quercetin | Homo sapiens (human) | IC50 | 15.7500 | 2 | 2 |
camostat mesylate | Homo sapiens (human) | IC50 | 31.6000 | 1 | 1 |
cyclotheonamide a | Homo sapiens (human) | IC50 | 0.7615 | 2 | 2 |
cyclotheonamide a | Homo sapiens (human) | Ki | 0.0905 | 2 | 2 |
ximelagatran | Homo sapiens (human) | Ki | 0.0020 | 1 | 1 |
otamixaban | Homo sapiens (human) | Ki | 4.0000 | 1 | 1 |
bms 740808 | Homo sapiens (human) | Ki | 0.0350 | 2 | 2 |
napsagatran | Homo sapiens (human) | Ki | 0.0003 | 2 | 2 |
talabostat | Homo sapiens (human) | Ki | 0.0020 | 1 | 1 |
n,n-(4-xylylidene)bisaminoguanidine | Homo sapiens (human) | Ki | 68.0000 | 1 | 1 |
ym 60828 | Homo sapiens (human) | IC50 | 0.0077 | 1 | 1 |
ym 60828 | Homo sapiens (human) | Ki | 40.0000 | 3 | 3 |
rivaroxaban | Homo sapiens (human) | Ki | 1.0000 | 1 | 1 |
n-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(l)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride | Homo sapiens (human) | Ki | 0.4900 | 2 | 2 |
dpc 423 | Homo sapiens (human) | Ki | 4.7321 | 5 | 10 |
gw 813893 | Homo sapiens (human) | Ki | 0.3670 | 2 | 2 |
l 374087 | Homo sapiens (human) | Ki | 0.0005 | 7 | 7 |
darexaban | Homo sapiens (human) | Ki | 100.0000 | 1 | 1 |
lb 30057 | Homo sapiens (human) | Ki | 0.0004 | 6 | 6 |
darexaban glucuronide | Homo sapiens (human) | Ki | 100.0000 | 1 | 1 |
apixaban | Homo sapiens (human) | Ki | 2.3250 | 3 | 4 |
betrixaban | Homo sapiens (human) | IC50 | 11.5045 | 4 | 4 |
rpr 120844 | Homo sapiens (human) | Ki | 1.0000 | 1 | 1 |
n-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide | Homo sapiens (human) | IC50 | 1.0000 | 1 | 1 |
(z,z)-babch | Homo sapiens (human) | Ki | 0.5050 | 4 | 4 |
anabaenopeptin b | Homo sapiens (human) | IC50 | 1.6000 | 1 | 1 |
dysinosin a | Homo sapiens (human) | IC50 | 0.0460 | 1 | 1 |
dysinosin a | Homo sapiens (human) | Ki | 0.4510 | 2 | 2 |
PF-00835231 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
mk-7009 | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
grassystatin a | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
rpx7009 | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
Drugs with Activation Measurements
Drugs with Other Measurements
Fragment Binding Can Be Either More Enthalpy-Driven or Entropy-Driven: Crystal Structures and Residual Hydration Patterns Suggest Why.Journal of medicinal chemistry, , Sep-10, Volume: 58, Issue:17, 2015
Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 1. Models without explicit constrained water.Journal of medicinal chemistry, , Jun-06, Volume: 45, Issue:12, 2002
GRID/CPCA: a new computational tool to design selective ligands.Journal of medicinal chemistry, , Aug-10, Volume: 43, Issue:16, 2000
Design and synthesis of potent and highly selective thrombin inhibitors.Journal of medicinal chemistry, , Nov-11, Volume: 37, Issue:23, 1994
Synthesis and evaluation of 4-substituted benzylamine derivatives as beta-tryptase inhibitors.Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 16, Issue:11, 2006
Design of potent selective zinc-mediated serine protease inhibitors.Nature, , Feb-05, Volume: 391, Issue:6667, 1998
Design, synthesis, and biological activity of novel purine and bicyclic pyrimidine factor Xa inhibitors.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 8, Issue:16, 1998
Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme faJournal of medicinal chemistry, , Sep-10, Volume: 41, Issue:19, 1998
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.Bioorganic & medicinal chemistry letters, , 12-15, Volume: 29, Issue:24, 2019
Development of irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator.Journal of medicinal chemistry, , May-06, Volume: 47, Issue:10, 2004
Why Some Targets Benefit from beyond Rule of Five Drugs.Journal of medicinal chemistry, , 11-27, Volume: 62, Issue:22, 2019
New proline mimetics: synthesis of thrombin inhibitors incorporating cyclopentane- and cyclopentenedicarboxylic acid templates in the P2 position. Binding conformation investigated by X-ray crystallography.Journal of medicinal chemistry, , May-04, Volume: 43, Issue:9, 2000
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
Novel acylguanidine containing thrombin inhibitors with reduced basicity at the P1 moiety.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 8, Issue:24, 1998
Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs.European journal of medicinal chemistry, , Jan-15, Volume: 228, 2022
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.Journal of medicinal chemistry, , 03-22, Volume: 61, Issue:6, 2018
Design, synthesis and antithrombotic evaluation of novel non-peptide thrombin inhibitors.Bioorganic & medicinal chemistry, , 01-15, Volume: 25, Issue:2, 2017
Design, synthesis and structural exploration of novel fluorinated dabigatran derivatives as direct thrombin inhibitors.European journal of medicinal chemistry, , Volume: 96, 2015
Design, synthesis and antithrombotic evaluation of novel dabigatran etexilate analogs, a new series of non-peptides thrombin inhibitors.Bioorganic & medicinal chemistry, , Dec-01, Volume: 23, Issue:23, 2015
Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 23, Issue:17, 2013
Anti-Helicobacter pylori and thrombin inhibitory components from Chinese dragon's blood, Dracaena cochinchinensis.Journal of natural products, , Volume: 70, Issue:10, 2007
In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
3,6-disubstituted coumarins as mechanism-based inhibitors of thrombin and factor Xa.Journal of medicinal chemistry, , Dec-01, Volume: 48, Issue:24, 2005
Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide.Journal of medicinal chemistry, , Aug-14, Volume: 46, Issue:17, 2003
Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664.Bioorganic & medicinal chemistry letters, , Jan-07, Volume: 12, Issue:1, 2002
Thrombin active site inhibitors: chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogues.Bioorganic & medicinal chemistry letters, , Jan-07, Volume: 12, Issue:1, 2002
Unique overlap in the prerequisites for thrombin inhibition and oral bioavailability resulting in potent oral antithrombotics.Journal of medicinal chemistry, , Sep-26, Volume: 45, Issue:20, 2002
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
Protease inhibitors: synthesis and QSAR study of novel classes of nonbasic thrombin inhibitors incorporating sulfonylguanidine and O-methylsulfonylisourea moieties at P1.Journal of medicinal chemistry, , May-04, Volume: 43, Issue:9, 2000
Solution-phase and solid-phase synthesis of novel transition state inhibitors of coagulation enzymes incorporating a piperidinyl moiety.Bioorganic & medicinal chemistry letters, , May-03, Volume: 9, Issue:9, 1999
Potent thrombin inhibitors that probe the S1 subsite: tripeptide transition state analogues based on a heterocycle-activated carbonyl group.Journal of medicinal chemistry, , Aug-02, Volume: 39, Issue:16, 1996
Design and synthesis of potent and highly selective thrombin inhibitors.Journal of medicinal chemistry, , Nov-11, Volume: 37, Issue:23, 1994
Factor Xa inhibitors: next-generation antithrombotic agents.Journal of medicinal chemistry, , Sep-09, Volume: 53, Issue:17, 2010
Discovery of N-[(1R,2S,5S)-2-{[(5-chloroindol-2-yl)carbonyl]amino}-5-(dimethylcarbamoyl)cyclohexyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide hydrochloride: a novel, potent and orally active direct inhibitor of factor Xa.Bioorganic & medicinal chemistry, , Feb-01, Volume: 17, Issue:3, 2009
Orally active factor Xa inhibitors: investigation of a novel series of 3-amidinophenylsulfonamide derivatives using an amidoxime prodrug strategy.Bioorganic & medicinal chemistry letters, , Aug-15, Volume: 18, Issue:16, 2008
Prodrug-based design, synthesis, and biological evaluation of N-benzenesulfonylpiperidine derivatives as novel, orally active factor Xa inhibitors.Bioorganic & medicinal chemistry, , Jun-15, Volume: 15, Issue:12, 2007
PRO_SELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors.Journal of medicinal chemistry, , Mar-14, Volume: 45, Issue:6, 2002
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
GRID/CPCA: a new computational tool to design selective ligands.Journal of medicinal chemistry, , Aug-10, Volume: 43, Issue:16, 2000
Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors.Journal of medicinal chemistry, , May-20, Volume: 42, Issue:10, 1999
Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors.Journal of medicinal chemistry, , Apr-15, Volume: 37, Issue:8, 1994
Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.Bioorganic & medicinal chemistry, , Feb-15, Volume: 16, Issue:4, 2008
In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Inhibitors of serine proteases as potential therapeutic agents: the road from thrombin to tryptase to cathepsin G.Journal of medicinal chemistry, , Feb-12, Volume: 47, Issue:4, 2004
Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664.Bioorganic & medicinal chemistry letters, , Jan-07, Volume: 12, Issue:1, 2002
Thrombin active site inhibitors: chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogues.Bioorganic & medicinal chemistry letters, , Jan-07, Volume: 12, Issue:1, 2002
Retro-binding thrombin active site inhibitors: identification of an orally active inhibitor of thrombin catalytic activity.Bioorganic & medicinal chemistry letters, , Nov-04, Volume: 12, Issue:21, 2002
Dibasic benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors: 2. Sidechain optimization and demonstration of in vivo efficacy.Bioorganic & medicinal chemistry letters, , Mar-08, Volume: 9, Issue:5, 1999
1,2-disubstituted cyclohexane derived tripeptide aldehydes as novel selective thrombin inhibitors.Bioorganic & medicinal chemistry letters, , May-19, Volume: 8, Issue:10, 1998
Potent thrombin inhibitors that probe the S1 subsite: tripeptide transition state analogues based on a heterocycle-activated carbonyl group.Journal of medicinal chemistry, , Aug-02, Volume: 39, Issue:16, 1996
Retro-binding tripeptide thrombin active-site inhibitors: discovery, synthesis, and molecular modeling.Journal of medicinal chemistry, , Jul-08, Volume: 37, Issue:14, 1994
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
Design and synthesis of potent and selective 5,6-fused heterocyclic thrombin inhibitors.Bioorganic & medicinal chemistry letters, , Apr-05, Volume: 9, Issue:7, 1999
The solution conformation of (D)Phe-Pro-containing peptides: implications on the activity of Ac-(D)Phe-Pro-boroArg-OH, a potent thrombin inhibitor.Journal of medicinal chemistry, , Jun-25, Volume: 36, Issue:13, 1993
Fibrinolysis Inhibitors: Potential Drugs for the Treatment and Prevention of Bleeding.Journal of medicinal chemistry, , 02-27, Volume: 63, Issue:4, 2020
Design, synthesis, and SAR of a series of activated protein C (APC) inhibitors with selectivity against thrombin for the treatment of haemophilia.Bioorganic & medicinal chemistry letters, , Feb-01, Volume: 24, Issue:3, 2014
Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug.Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 23, Issue:17, 2013
Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety.Bioorganic & medicinal chemistry letters, , May-15, Volume: 16, Issue:10, 2006
Orally active thrombin inhibitors. Part 2: optimization of the P2-moiety.Bioorganic & medicinal chemistry letters, , May-15, Volume: 16, Issue:10, 2006
D-Phe-Pro-Arg type thrombin inhibitors: unexpected selectivity by modification of the P1 moiety.Bioorganic & medicinal chemistry letters, , Jun-16, Volume: 13, Issue:12, 2003
Synthesis of novel thrombin inhibitors. Use of ring-closing metathesis reactions for synthesis of P2 cyclopentene- and cyclohexenedicarboxylic acid derivatives.Journal of medicinal chemistry, , Mar-27, Volume: 46, Issue:7, 2003
Noncovalent tripeptidic thrombin inhibitors incorporating amidrazone, amine and amidine functions at P1.Bioorganic & medicinal chemistry letters, , Apr-08, Volume: 12, Issue:7, 2002
Unique overlap in the prerequisites for thrombin inhibition and oral bioavailability resulting in potent oral antithrombotics.Journal of medicinal chemistry, , Sep-26, Volume: 45, Issue:20, 2002
New proline mimetics: synthesis of thrombin inhibitors incorporating cyclopentane- and cyclopentenedicarboxylic acid templates in the P2 position. Binding conformation investigated by X-ray crystallography.Journal of medicinal chemistry, , May-04, Volume: 43, Issue:9, 2000
Phenyltriazolinones as potent factor Xa inhibitors.Bioorganic & medicinal chemistry letters, , Feb-15, Volume: 20, Issue:4, 2010
Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 18, Issue:2, 2008
Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: discovery of novel, highly potent inhibitors of Factor Xa.Bioorganic & medicinal chemistry letters, , Jul-15, Volume: 18, Issue:14, 2008
Design, structure-activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitors.Bioorganic & medicinal chemistry letters, , Dec-01, Volume: 17, Issue:23, 2007
1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blooBioorganic & medicinal chemistry letters, , Aug-01, Volume: 16, Issue:15, 2006
Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa.Bioorganic & medicinal chemistry letters, , Jul-15, Volume: 16, Issue:14, 2006
Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors.Bioorganic & medicinal chemistry letters, , Apr-01, Volume: 16, Issue:7, 2006
Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties.Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 16, Issue:21, 2006
Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs.European journal of medicinal chemistry, , Jan-15, Volume: 228, 2022
Acylated 1Journal of medicinal chemistry, , 11-12, Volume: 63, Issue:21, 2020
Design of Small-Molecule Active-Site Inhibitors of the S1A Family Proteases as Procoagulant and Anticoagulant Drugs.Journal of medicinal chemistry, , 05-10, Volume: 61, Issue:9, 2018
The selectivity and bioavailability improvement of novel oral anticoagulants: An overview.European journal of medicinal chemistry, , Feb-25, Volume: 146, 2018
Design, synthesis and antithrombotic evaluation of novel non-peptide thrombin inhibitors.Bioorganic & medicinal chemistry, , 01-15, Volume: 25, Issue:2, 2017
Novel dabigatran derivatives with a fluorine atom at the C-2 position of the terminal benzene ring: Design, synthesis and anticoagulant activity evaluation.European journal of medicinal chemistry, , Jan-27, Volume: 126, 2017
Molecular design, synthesis and anticoagulant activity evaluation of fluorinated dabigatran analogues.Bioorganic & medicinal chemistry, , 06-15, Volume: 24, Issue:12, 2016
Molecular modeling studies, synthesis and biological evaluation of dabigatran analogues as thrombin inhibitors.Bioorganic & medicinal chemistry, , Jan-15, Volume: 24, Issue:2, 2016
Design, synthesis, anticoagulant activity evaluation and molecular docking studies of a class of N-ethyl dabigatran derivatives.European journal of medicinal chemistry, , Sep-14, Volume: 120, 2016
Design, synthesis and structural exploration of novel fluorinated dabigatran derivatives as direct thrombin inhibitors.European journal of medicinal chemistry, , Volume: 96, 2015
Design, synthesis and antithrombotic evaluation of novel dabigatran etexilate analogs, a new series of non-peptides thrombin inhibitors.Bioorganic & medicinal chemistry, , Dec-01, Volume: 23, Issue:23, 2015
5-Chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and factor Xa inhibitor.Journal of medicinal chemistry, , Dec-12, Volume: 56, Issue:23, 2013
Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores.European journal of medicinal chemistry, , Volume: 64, 2013
Fluorinated dual antithrombotic compounds based on 1,4-benzoxazine scaffold.European journal of medicinal chemistry, , Volume: 50, 2012
Synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing a cleavable moiety with anti-platelet activity.European journal of medicinal chemistry, , Volume: 57, 2012
Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).Journal of medicinal chemistry, , Apr-26, Volume: 55, Issue:8, 2012
Structure-based design of novel potent nonpeptide thrombin inhibitors.Journal of medicinal chemistry, , Apr-25, Volume: 45, Issue:9, 2002
Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors.Journal of medicinal chemistry, , Feb-23, Volume: 49, Issue:4, 2006
Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).Journal of molecular biology, , Nov-19, Volume: 344, Issue:2, 2004
A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.Journal of molecular biology, , Apr-13, Volume: 307, Issue:5, 2001
Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.Chemistry & biology, , Volume: 7, Issue:4, 2000
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.Journal of medicinal chemistry, , Apr-14, Volume: 54, Issue:7, 2011
Design and synthesis of macrocyclic indoles targeting blood coagulation cascade Factor XIa.Bioorganic & medicinal chemistry letters, , Dec-01, Volume: 20, Issue:23, 2010
Unique overlap in the prerequisites for thrombin inhibition and oral bioavailability resulting in potent oral antithrombotics.Journal of medicinal chemistry, , Sep-26, Volume: 45, Issue:20, 2002
Cyclotheonamides E2 and E3, new potent serine protease inhibitors from the marine sponge of the genus Theonella.Journal of natural products, , Volume: 61, Issue:5, 1998
Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 18, Issue:2, 2008
1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blooBioorganic & medicinal chemistry letters, , Aug-01, Volume: 16, Issue:15, 2006
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
Design and synthesis of potent and highly selective thrombin inhibitors.Journal of medicinal chemistry, , Nov-11, Volume: 37, Issue:23, 1994
Factor Xa inhibitors: next-generation antithrombotic agents.Journal of medicinal chemistry, , Sep-09, Volume: 53, Issue:17, 2010
PRO_SELECT: combining structure-based drug design and array-based chemistry for rapid lead discovery. 2. The development of a series of highly potent and selective factor Xa inhibitors.Journal of medicinal chemistry, , Mar-14, Volume: 45, Issue:6, 2002
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase.Journal of medicinal chemistry, , Jul-13, Volume: 49, Issue:14, 2006
3-Amidinophenylalanine-based inhibitors of urokinase.Bioorganic & medicinal chemistry letters, , Nov-01, Volume: 9, Issue:21, 1999
Factor Xa inhibitors: next-generation antithrombotic agents.Journal of medicinal chemistry, , Sep-09, Volume: 53, Issue:17, 2010
Phenyltriazolinones as potent factor Xa inhibitors.Bioorganic & medicinal chemistry letters, , Feb-15, Volume: 20, Issue:4, 2010
Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 17, Issue:5, 2007
Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Sulfonamide-related conformational effects and their importance in structure-based design.Bioorganic & medicinal chemistry letters, , May-15, Volume: 17, Issue:10, 2007
Selective and dual action orally active inhibitors of thrombin and factor Xa.Bioorganic & medicinal chemistry letters, , May-15, Volume: 17, Issue:10, 2007
The selectivity and bioavailability improvement of novel oral anticoagulants: An overview.European journal of medicinal chemistry, , Feb-25, Volume: 146, 2018
Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 18, Issue:6, 2008
Unexpected enhancement of thrombin inhibitor potency with o-aminoalkylbenzylamides in the P1 position.Bioorganic & medicinal chemistry letters, , Oct-20, Volume: 13, Issue:20, 2003
Non-covalent thrombin inhibitors featuring P(3)-heterocycles with P(1)-monocyclic arginine surrogates.Bioorganic & medicinal chemistry letters, , Apr-22, Volume: 12, Issue:8, 2002
C6 modification of the pyridinone core of thrombin inhibitor L-374,087 as a means of enhancing its oral absorption.Bioorganic & medicinal chemistry letters, , Jul-07, Volume: 8, Issue:13, 1998
Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates.Journal of medicinal chemistry, , Nov-05, Volume: 41, Issue:23, 1998
L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor.Bioorganic & medicinal chemistry letters, , Apr-07, Volume: 8, Issue:7, 1998
Noncovalent tripeptidic thrombin inhibitors incorporating amidrazone, amine and amidine functions at P1.Bioorganic & medicinal chemistry letters, , Apr-08, Volume: 12, Issue:7, 2002
Noncovalent thrombin inhibitors incorporating an imidazolylethynyl P1.Bioorganic & medicinal chemistry letters, , Dec-18, Volume: 10, Issue:24, 2000
Fluorobenzamidrazone thrombin inhibitors: influence of fluorine on enhancing oral absorption.Bioorganic & medicinal chemistry letters, , Sep-06, Volume: 9, Issue:17, 1999
Discovery of LB30057, a benzamidrazone-based selective oral thrombin inhibitor.Bioorganic & medicinal chemistry letters, , Mar-17, Volume: 8, Issue:6, 1998
Potent and efficacious thienylamidine-incorporated thrombin inhibitors.Bioorganic & medicinal chemistry letters, , Jul-07, Volume: 8, Issue:13, 1998
Benzylamine-based selective and orally bioavailable inhibitors of thrombin.Bioorganic & medicinal chemistry letters, , Sep-22, Volume: 8, Issue:18, 1998
Phenyltriazolinones as potent factor Xa inhibitors.Bioorganic & medicinal chemistry letters, , Feb-15, Volume: 20, Issue:4, 2010
Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation faJournal of medicinal chemistry, , Nov-01, Volume: 50, Issue:22, 2007
Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors.Bioorganic & medicinal chemistry, , 12-15, Volume: 26, Issue:23-24, 2018
Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin- 4(1H)-one derivatives as potential fXa inhibitors.European journal of medicinal chemistry, , Jan-05, Volume: 125, 2017
Identification of anthranilamide derivatives as potential factor Xa inhibitors: drug design, synthesis and biological evaluation.European journal of medicinal chemistry, , May-05, Volume: 95, 2015
Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor.Bioorganic & medicinal chemistry letters, , Apr-15, Volume: 19, Issue:8, 2009
Synthesis, characterization, and structure-activity relationships of amidine-substituted (bis)benzylidene-cycloketone olefin isomers as potent and selective factor Xa inhibitors.Journal of medicinal chemistry, , Dec-30, Volume: 42, Issue:26, 1999
Design, synthesis, and biological activity of novel purine and bicyclic pyrimidine factor Xa inhibitors.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 8, Issue:16, 1998
Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme faJournal of medicinal chemistry, , Sep-10, Volume: 41, Issue:19, 1998
(Z,Z)-2,7-Bis(4-amidinobenzylidene)cycloheptan-1-one: identification of a highly active inhibitor of blood coagulation factor Xa.Journal of medicinal chemistry, , Sep-10, Volume: 41, Issue:19, 1998
Preparation of L-proline based aeruginosin 298-A analogs: optimization of the P1-moiety.Bioorganic & medicinal chemistry letters, , Jul-15, Volume: 19, Issue:14, 2009
From natural products to achiral drug prototypes: potent thrombin inhibitors based on P2/P3 dihydropyrid-2-one core motifs.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 19, Issue:18, 2009
Dysinosins B-D, inhibitors of factor VIIa and thrombin from the Australian sponge Lamellodysidea chlorea.Journal of natural products, , Volume: 67, Issue:8, 2004
Enables
This protein enables 8 target(s):
Target | Category | Definition |
lipopolysaccharide binding | molecular function | Binding to a lipopolysaccharide. [PMID:11079463] |
serine-type endopeptidase activity | molecular function | Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a catalytic mechanism that involves a catalytic triad consisting of a serine nucleophile that is activated by a proton relay involving an acidic residue (e.g. aspartate or glutamate) and a basic residue (usually histidine). [GOC:mah, https://www.ebi.ac.uk/merops/about/glossary.shtml#CATTYPE] |
signaling receptor binding | molecular function | Binding to one or more specific sites on a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function. [GOC:bf, GOC:ceb, ISBN:0198506732] |
calcium ion binding | molecular function | Binding to a calcium ion (Ca2+). [GOC:ai] |
protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
growth factor activity | molecular function | The function that stimulates a cell to grow or proliferate. Most growth factors have other actions besides the induction of cell growth or proliferation. [ISBN:0815316194] |
heparin binding | molecular function | Binding to heparin, a member of a group of glycosaminoglycans found mainly as an intracellular component of mast cells and which consist predominantly of alternating alpha-(1->4)-linked D-galactose and N-acetyl-D-glucosamine-6-sulfate residues. [GOC:jl, ISBN:0198506732] |
thrombospondin receptor activity | molecular function | Combining with thrombospondin and transmitting the signal to initiate a change in cell activity. [GOC:BHF, GOC:signaling, GOC:vk] |
Located In
This protein is located in 7 target(s):
Target | Category | Definition |
extracellular region | cellular component | The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite. [GOC:go_curators] |
extracellular space | cellular component | That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid. [ISBN:0198547684] |
endoplasmic reticulum lumen | cellular component | The volume enclosed by the membranes of the endoplasmic reticulum. [ISBN:0198547684] |
Golgi lumen | cellular component | The volume enclosed by the membranes of any cisterna or subcompartment of the Golgi apparatus, including the cis- and trans-Golgi networks. [GOC:mah] |
plasma membrane | cellular component | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. [ISBN:0716731363] |
extracellular exosome | cellular component | A vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm. [GOC:BHF, GOC:mah, GOC:vesicles, PMID:15908444, PMID:17641064, PMID:19442504, PMID:19498381, PMID:22418571, PMID:24009894] |
blood microparticle | cellular component | A phospholipid microvesicle that is derived from any of several cell types, such as platelets, blood cells, endothelial cells, or others, and contains membrane receptors as well as other proteins characteristic of the parental cell. Microparticles are heterogeneous in size, and are characterized as microvesicles free of nucleic acids. [GOC:BHF, GOC:mah, PMID:16373184] |
Active In
This protein is active in 2 target(s):
Target | Category | Definition |
collagen-containing extracellular matrix | cellular component | An extracellular matrix consisting mainly of proteins (especially collagen) and glycosaminoglycans (mostly as proteoglycans) that provides not only essential physical scaffolding for the cellular constituents but can also initiate crucial biochemical and biomechanical cues required for tissue morphogenesis, differentiation and homeostasis. The components are secreted by cells in the vicinity and form a sheet underlying or overlying cells such as endothelial and epithelial cells. [GOC:BHF, GOC:rph, PMID:21123617] |
extracellular space | cellular component | That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid. [ISBN:0198547684] |
Involved In
This protein is involved in 33 target(s):
Target | Category | Definition |
positive regulation of protein phosphorylation | biological process | Any process that activates or increases the frequency, rate or extent of addition of phosphate groups to amino acids within a protein. [GOC:hjd] |
proteolysis | biological process | The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their peptide bonds. [GOC:bf, GOC:mah] |
acute-phase response | biological process | An acute inflammatory response that involves non-antibody proteins whose concentrations in the plasma increase in response to infection or injury of homeothermic animals. [ISBN:0198506732] |
cell surface receptor signaling pathway | biological process | The series of molecular signals initiated by an extracellular ligand binding to a receptor located on the cell surface. The pathway ends with regulation of a downstream cellular process, e.g. transcription. [GOC:signaling] |
G protein-coupled receptor signaling pathway | biological process | The series of molecular signals initiated by a ligand binding to its receptor, in which the activated receptor promotes the exchange of GDP for GTP on the alpha-subunit of an associated heterotrimeric G-protein complex. The GTP-bound activated alpha-G-protein then dissociates from the beta- and gamma-subunits to further transmit the signal within the cell. The pathway begins with receptor-ligand interaction, and ends with regulation of a downstream cellular process. The pathway can start from the plasma membrane, Golgi or nuclear membrane. [GOC:bf, GOC:mah, PMID:16902576, PMID:24568158, Wikipedia:G_protein-coupled_receptor] |
blood coagulation | biological process | The sequential process in which the multiple coagulation factors of the blood interact, ultimately resulting in the formation of an insoluble fibrin clot; it may be divided into three stages: stage 1, the formation of intrinsic and extrinsic prothrombin converting principle; stage 2, the formation of thrombin; stage 3, the formation of stable fibrin polymers. [PMID:30700128] |
positive regulation of cell population proliferation | biological process | Any process that activates or increases the rate or extent of cell proliferation. [GOC:go_curators] |
regulation of cell shape | biological process | Any process that modulates the surface configuration of a cell. [GOC:dph, GOC:go_curators, GOC:tb] |
response to wounding | biological process | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating damage to the organism. [GOC:go_curators] |
negative regulation of platelet activation | biological process | Any process that decreases the rate or frequency of platelet activation. Platelet activation is a series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. [GOC:BHF, GOC:dph, GOC:tb] |
platelet activation | biological process | A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable hemostatic plug. [http://www.graylab.ac.uk/omd/] |
regulation of blood coagulation | biological process | Any process that modulates the frequency, rate or extent of blood coagulation. [GOC:mah] |
positive regulation of blood coagulation | biological process | Any process that activates or increases the frequency, rate or extent of blood coagulation. [GOC:mah] |
positive regulation of cell growth | biological process | Any process that activates or increases the frequency, rate, extent or direction of cell growth. [GOC:go_curators] |
positive regulation of insulin secretion | biological process | Any process that activates or increases the frequency, rate or extent of the regulated release of insulin. [GOC:mah] |
positive regulation of collagen biosynthetic process | biological process | Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of collagen, any of a group of fibrous proteins of very high tensile strength that form the main component of connective tissue in animals. [GOC:mah] |
fibrinolysis | biological process | A process that solubilizes fibrin in the bloodstream of a multicellular organism, chiefly by the proteolytic action of plasmin. [GOC:jl, PMID:15842654] |
negative regulation of proteolysis | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of the hydrolysis of a peptide bond or bonds within a protein. [GOC:go_curators] |
positive regulation of receptor signaling pathway via JAK-STAT | biological process | Any process that activates or increases the frequency, rate or extent of the JAK-STAT signaling pathway activity. [GOC:bf] |
negative regulation of astrocyte differentiation | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of astrocyte differentiation. [GOC:vp, PMID:15139015] |
positive regulation of release of sequestered calcium ion into cytosol | biological process | Any process that activates or increases the frequency, rate or extent of the release into the cytosolic compartment of calcium ions sequestered in the endoplasmic reticulum or mitochondria. [GOC:ai] |
regulation of cytosolic calcium ion concentration | biological process | Any process involved in the maintenance of an internal steady state of calcium ions within the cytosol of a cell or between the cytosol and its surroundings. [GOC:ai, GOC:mah, GOC:rph] |
cytolysis by host of symbiont cells | biological process | The killing by an organism of a cell in its symbiont organism by means of the rupture of cell membranes and the loss of cytoplasm. The symbiont is defined as the smaller of the organisms involved in a symbiotic interaction. [GOC:add] |
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction | biological process | Any process that activates or increases the frequency, rate or extent of phosphatidylinositol 3-kinase/protein kinase B signal transduction. [GOC:ai] |
negative regulation of fibrinolysis | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of fibrinolysis, an ongoing process that solubilizes fibrin, resulting in the removal of small blood clots. [GOC:ai] |
antimicrobial humoral immune response mediated by antimicrobial peptide | biological process | An immune response against microbes mediated by anti-microbial peptides in body fluid. [PMID:15761415, PMID:24287494] |
neutrophil-mediated killing of gram-negative bacterium | biological process | The directed killing of a gram-negative bacterium by a neutrophil. [GOC:add, ISBN:0781765196] |
positive regulation of lipid kinase activity | biological process | Any process that increases the frequency, rate or extent of lipid kinase activity, the catalysis of the transfer of a phosphate group, usually from ATP, to a simple or complex lipid. [GOC:dph, GOC:tb] |
negative regulation of cytokine production involved in inflammatory response | biological process | Any process that stops, prevents or reduces the frequency, rate or extent of cytokine production involved in inflammatory response. [GOC:TermGenie] |
positive regulation of protein localization to nucleus | biological process | Any process that activates or increases the frequency, rate or extent of protein localization to nucleus. [GOC:TermGenie] |
positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway | biological process | Any process that activates or increases the frequency, rate or extent of phospholipase C-activating G protein-coupled receptor signaling pathway. [GOC:BHF, GOC:TermGenie] |
ligand-gated ion channel signaling pathway | biological process | The series of molecular signals initiated by activation of a ligand-gated ion channel on the surface of a cell. The pathway begins with binding of an extracellular ligand to a ligand-gated ion channel and ends with a molecular function that directly regulates a downstream cellular process, e.g. transcription. [GOC:bhm, PMID:25869137] |
positive regulation of reactive oxygen species metabolic process | biological process | Any process that activates or increases the frequency, rate or extent of reactive oxygen species metabolic process. [GOC:mah] |